SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

Steven Spielberg

SIOUX FALLS, S.D., September 28, 2021–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer […]

Subscribe US Now